Author(s):
N. N. Gavrilova, I.A. Ratnikova, A. K. Sadanov, S. E. Orazymbet, E. Zh. Shorabaev, L. E. Protasiuk
Email(s):
iratnikova@list.ru
DOI:
10.52711/0974-360X.2023.00670 
Address:
N. N. Gavrilova1, I.A. Ratnikova1*, A. K. Sadanov1, S. E. Orazymbet1, E. Zh. Shorabaev2, L. E. Protasiuk1
1Research and Production Center for Microbiology and Virology, 105 Bogenbai Batyr str., Almaty, 050010, Kazakhstan.
2Industrial Microbiology LLP, 89/44 Al-Farabi ave., Almaty, 050060, Kazakhstan.
*Corresponding Author
Published In:
Volume - 16,
Issue - 9,
Year - 2023
ABSTRACT:
The study aimed to develop a technology for the production of a finished form of medicinal probiotic agents against human intestinal infections based on active strains of lactic acid and propionic acid bacteria with a wide range of biological activity and resistance to antibiotics. From the laboratory collection of lactic acid and propionic acid bacteria isolated from the intestines of healthy people, two associations of bacteria were compiled with antagonism against test cultures of Staphylococcus aureus, Salmonella gallinarum, Mycobacterium B5, Candida albicans, Pasteurella multocida, Bacillus subtilis, Escherichia coli 8739, Klebsiella pneumoniae ATCC 700603 and ATCC BAA 2524, Staphylococcus aureus 3316 and 9, Salmonella enteritidis 35382, and Pseudomonas aeruginosa 835, as well as the ability to produce hydrolytic enzymes amylase and proteinase, B vitamins, and essential amino acids. The resistance of the selected associations of lactic acid and propionic acid bacteria to the used antibiotics has been studied, which will allow for using them, if necessary, in the complex therapy of diseases. Technology for the production of probiotic medication from these associations has been developed. It was found that the most active preparation in terms of bacterial titer and antagonistic activity and the most stable one during storage for 6 months was the liquid preparation obtained by growing association No. 2 (L. plantarum 2v/A-6+L. brevis B-3/A-26+L. acidophilus 27w/60+P. shermanii 8) on nutrient medium No. 1 (De Man, Rogosa and Sharpe agar with CoCl2) using 7% sucrose and 1.5% gelatin as a protector. The liquid preparation from association No. 5 grown on medium No. 1 showed a more complete preservation of production-valuable signs during storage compared to the results of using nutrient medium No. 4, while the use of protector No. 1 was more optimal. To test the stability during the storage of dry preparation forms, an accelerated method was used by warming them up for 15 minutes at 60°C. It was found that after warming up, the best preservation of viable bacterial cells was observed in association No. 2 on nutrient media No. 1 and No. 4, in association No. 5 on medium No. 4 dried with protector No. 2 (7% sucrose and 1.5% gelatin + 7% skim milk powder), while the titer of bacteria was equal to 1.2×109, 3.5×108, and 2.0±0.2×108 colony-forming units/g, respectively. Antagonistic activity in these association variants was observed against all test cultures taken into the study with zones of suppression of their growth ranging from 10 to 24 mm.
Cite this article:
N. N. Gavrilova, I.A. Ratnikova, A. K. Sadanov, S. E. Orazymbet, E. Zh. Shorabaev, L. E. Protasiuk. Development of Technology for the production of finished forms of Medicinal probiotics. Research Journal of Pharmacy and Technology 2023; 16(9):4093-4. doi: 10.52711/0974-360X.2023.00670
Cite(Electronic):
N. N. Gavrilova, I.A. Ratnikova, A. K. Sadanov, S. E. Orazymbet, E. Zh. Shorabaev, L. E. Protasiuk. Development of Technology for the production of finished forms of Medicinal probiotics. Research Journal of Pharmacy and Technology 2023; 16(9):4093-4. doi: 10.52711/0974-360X.2023.00670 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2023-16-9-14
REFERENCES:
1. World Health Organization. World health statistics 2011. WHO Press, Geneva. 2011; 170 p.
2. Burayev G. Khamitov M. Lozovoy V. Aipov R. Lozovaya E. Akhmaltdinova L. Burayeva K. The Correction Methods of the Intestinal Microflora in Chronic Colonic Stasis by Siphon Enema and Probiotics as a Means of the Hirschsprung-associated Enterocolitis Prevention. Research J. Pharm. and Tech. 2020; 13(6):2601-2607. doi: 10.5958/0974-360X.2020.00463.1
3. Kumar G. Kumar Y. Kumar G. Kumar Tahlan A. Sero-characterization of intestinal and extra-intestinal Escherichia coli (E. coli) isolates from different geographical locations in India. Research J. Pharm. and Tech. 2022; 15(11):5239-4. doi: 10.52711/0974-360X.2022.00882
4. Laili RD. Martati E. Rifa’i M. Immunomodulator effect of Moringa oleifera Leaves Fermented by Lactobacillus plantarum FNCC 0137 on Salmonella typhi infected Balb/C Mice. Research J. Pharm. and Tech. 2019; 12(8):3595-3601. doi: 10.5958/0974-360X.2019.00613.9
5. Fatmawati S. Laili RD. Wuryandari MMRE. Martati E. Widyaningsih TD. Rifa’i M. Fermented Ethanolic Extract of Moringa oleifera leaves with Lactobacillus plantarum FNCC 0137 as Immunomodulators on Salmonella typhi-Infected Mice. Research J. Pharm. and Tech. 2020; 13(12):5777-5782. doi: 10.5958/0974-360X.2020.01007.0
6. Bunyan IA. Alkhuzaee QAJ. Detection of Curlibiogenesis genes among Enterobacter cloacae isolates and their role in biofilm formation in Al-Hilla City, Iraq. Research J. Pharm. and Tech. 2017; 10(10):3294-3300. doi: 10.5958/0974-360X.2017.00584.4
7. Muslem WH. Muslim SN. Ali ANM. Fayyad RJ. Detection of Disinfectant property of purified Amylopullulanase from Citrobacter freundii SW. Research J. Pharm. and Tech. 2022; 15(2):847-2. doi: 10.52711/0974-360X.2022.00141
8. Patel V. Mehta P. Kikani K. Goswami GK. Antibiotic Sensitivity Pattern of Clinically Isolated Klebsiella Species in C. U. Shah Hospital, Surendranagar. Research J. Pharm. and Tech. 2022; 15(5):1989-4. doi: 10.52711/0974-360X.2022.00330
9. Abbas HA. El-Saysed MA. Ganiny AM. Fattah AA. Antimicrobial Resistance Patterns of Proteus mirabilis isolates from Urinary tract, burn wound and Diabetic foot Infections. Research J. Pharm. and Tech. 2018; 11(1):249-252. doi: 10.5958/0974-360X.2018.00046.X
10. Sarkar A. Philip AM. Thakker DP. Wagh MS. Rao KVB. In vitro Antioxidant activity of extracellular L-glutaminase enzyme isolated from marine yeast Rhodotorula sp. DAMB1. Research J. Pharm. and Tech. 2020; 13(1):209-215. doi: 10.5958/0974-360X.2020.00042.6
11. Zam W. Dawod R. Overview of the Probiotics’ role in Gastrointestinal disorders. Research J. Pharm. and Tech. 2020; 13(11):5557-5561. doi: 10.5958/0974-360X.2020.00970.1
12. Lobzin YuV. Zakharenko SM. Plotnikov KP. Disbakterioz, ili polezny li antibiotiki [Disbacteriosis, and whether antibiotics are good for health]. Spets. literatura, St. Petersburg. 2002; 190 p.
13. Gardiner GE. Heinemann C. Baroja ML. Bruce AW. Beuerman D. Madrenas J. Reid G. Oral administration of the probiotic combination Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 for human intestinal applications. International Dairy Journal. 2002; 12(2-3):191-6. http://dx.doi.org/10.1016/S0958-6946(01)00138-8
14. Reniero R. Bruesson H. Rochat F. Von der Weid T. Blum-Sperisen S. Shtammy Lactobacillus, sposobstvuyushchie predotvrashcheniyu diarei, vyzvannoi rotavirusami [Lactobacillus strains that help prevent diarrhea caused by rotaviruses]. Pat. 04000555 WO USA. 2004.
15. Savitskaya KI. Melnikova EF. Vorobyov AA. Zagalskaya NV. Mikroflora zhelchi pri khronicheskom pankreatite [Bile microflora in chronic pancreatitis]. Zhurnal mikrobiologii, Epidemiologii I Immunobiologii. 2003; 1:147.
16. Namazova-Baranova LS. Baranov AA. Antibiotic resistance in modern world. Pediatric Pharmacology. 2017; 14(5):341-54. doi: 10.15690/pf.v14i5.1782
17. Konakova AV. Kushakova KA. Vliyanie antibiotikov na organizm cheloveka [The influence of antibiotics on the human body]. Alleya nauki. 2019; 1(9(36)):91-4.
18. Hill C. Guarner F. Reid G. Gibson GR. Merenstein DJ. Pot B. Morelli L. Canani RB. Flint HJ. Salminen S. Calder PC. Sanders ME. Expert consensus document: The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews. Gastroenterology & Hepatology. 2014; 11(8):506-14. doi: 10.1038/nrgastro.2014.66
19. Kaibysheva VO. Nikonov EL. Probiotics from the standpoint of evidence-based medicine. Russian Journal of Evidence-Based Gastroenterology. 2019; 8(3):45 54. doi: 10.17116/dokgastro2019803145
20. Corr SC. Hill C. Gahan CGM. Chapter 1 Understanding the mechanisms by which probiotics inhibit gastrointestinal pathogens. Advances in Food and Nutrition Research. 2009; 56:1-15. doi: 10.1016/s1043-4526(08)00601-3
21. Rao RK. Samak G. Protection and restitution of gut barrier by probiotics: Nutritional and clinical implications. Current Nutrition and Food Science. 2013; 9(2):99-107. doi: 10.2174/1573401311309020004
22. Wells JM. Immunomodulatory mechanisms of lactobacilli. Microbial Cell Factories. 2011; 10:S17. doi: 10.1186/1475-2859-10-S1-S17
23. Nikolaeva SV. Zolotarev YuV. Gorelov AV. Primenenie probiotikov v meditsinskoi praktike [The use of antibiotics in applied medicine]. RMJ. Medical Review. 2018; 8(11):84-7.
24. Pedone CA. Arnaud CC. Postaire ER. Bouley CF. Reinert P. Multicentric study of the effect of milk fermented by Lactobacillus casei on the incidence of diarrhea. International Journal of Clinical Practice. 2000; 54(9):568-71.
25. Johnston BC. Supina AL. Vohra S. Probiotics for pediatric antibiotic-associated diarrhea: A meta-analysis of randomized placebo-controlled trials. Canadian Medical Association Journal. 2006; 175(4):377-83. doi: 10.1503/cmaj.051603
26. Goldenberg JZ. Ma SS. Saxton JD. Martzen MR. Vandvik PO. Thorlund K. Guyatt GH. Johnston BC. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database of Systematic Reviews. 2013; 5:CD006095. doi: 10.1002/14651858.cd006095.pub3
27. Sniffen JC. McFarland LV. Evans CT. Goldstein EJC. Choosing an appropriate probiotic product for your patient: An evidence-based practical guide. PLoS One. 2018; 13(12):e0209205. doi: 10.1371/journal.pone.0209205
28. Lionetti E. Francavilla R. Castellazzi AM. Arrigo T. Labò E. Leonardi S. Ciprandi G. Miraglia Del Giudice M. Salpietro V. Salpietro C. La Rosa M. Probiotics and Helicobacter pylori infection in children. Journal of Biological Regulators & Homeostatic Agents. 2012; 26(1):69-76.
29. Alfaleh K. Anabrees J. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database of Systematic Reviews. 2014; 4:CD005496. DOI: 10.1002/14651858
30. Fenton KA. Ison C. Johnson AP. Rudd E. Soltani M. Martin I. Nichols T. Livermore DM. GRASP collaboration. Ciprofloxacin resistance in Neisseria gonorrhoeae in England and Wales in 2002. Lancet. 2003; 361(9372):1867-9. DOI: 10.1016/S0140-6736(03)13489-7.
31. Taylor AL. Dunstan JA. Prescott SL. Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: A randomized controlled trial. The Journal of Allergy and Clinical Immunology. 2007; 119(1):184-91. doi: 10.1016/j.jaci.2006.08.036
32. Zajac AE. Adams AS. Turner JH. A systematic review and meta-analysis of probiotics for the treatment of allergic rhinitis. International Forum of Allergy & Rhinology. 2015; 5(6):524-32. doi: 10.1002/alr.21492
33. Abad CL. Safdar N. The role of Lactobacillus probiotics in the treatment or prevention of urogenital infections - A systematic review. Journal of Chemotherapy. 2009; 21(3):243-52. doi: 10.1179/joc.2009.21.3.243
34. Usenko DV. Gorelova EA. Probiotiki v lechenii ostrykh kishechnykh infektsii u detei s soputstvuyushchim atopicheskim dermatitom [Probiotics in the treatment of acute intestinal infections in children with concomitant atopic dermatitis]. RMJ. Medical Review. 2014; 22(24):1780.
35. World Gastroenterology Organisation Global Guidelines. Probiotics and Prebiotics. February 2017. Available at: https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-english-2017.pdf
36. Millette M. Nguyen A. Amine KM. Lacroix M. Gastrointestinal survival of bacteria in commercial probiotic products. International Journal of Probiotics and Prebiotics. 2013; 8(4):149-56.
37. Kosgey JC. Jia L. Fang Y. Yang J. Gao L. Wang J. Nyamao R. Cheteu M. Tong D. Wekesa V. Vasilyeva N. Zhang F. Probiotics as antifungal agents: Experimental confirmation and future prospects. Journal of Microbiological Methods. 2019; 162:28-37. doi: 10.1016/j.mimet.2019.05.001
38. Fenster K. Freeburg B. Hollard C. Wong C. Rønhave Laursen R. Ouwehand AC. The production and delivery of probiotics: A review of a practical approach. Microorganisms. 2019; 7(3):83. doi: 10.3390/microorganisms7030083
39. Bianchi L. Laghi L. Correani V. Schifano E. Landi C. Uccelletti D. Mattei B. A combined proteomics, metabolomics, and in vivo analysis approach for the characterization of probiotics in large-scale production. Biomolecules. 2020; 10(1):157. doi: 10.3390/biom10010157
40. Savitskaya IS. Shokataeva DKh. Talipova A. Immobilizatsiya probiotikov v polisakharidnye matritsy dlya zashchity ot stressovykh faktorov [Immobilization of probiotics into polysaccharide matrixes for protection from stress factors]. In Modern synthetic methodologies for drugs and functional materials (MOSM 2021): V International scientific and practical conference: Materials and reports, Ekaterinburg, Russia, November 8-12, 2021. Individual entrepreneur Ekaterina Vyacheslavovna Shestakova, Ekaterinburg. 2021; 58. Available at: https://elar.urfu.ru/bitstream/10995/110527/1/978-5-6044427-5-3_2021_039.pdf
41. Makarevich OV. Gaponova II. Shchetko VA. Romanova LV. Ispolzovanie metodov mikrokapsulirovaniya mikroorganizmov v biotekhnologii proizvodstva probioticheskikh preparatov [Application of microcapsulation methods in biotechnology of probiotic preparations]. In Mikrobnyye biotekhnologii: Fundamental'nyye i prikladnyye aspekty. Sbornik nauchnykh trudov [Microbial biotechnology: Fundamental and applied aspects. Collection of scientific papers], Vol. 11, Edited by Kolomiyets EI. Izdatel'skiy dom "Belorusskaya nauka", Minsk. 2019; 474-488.
42. Romyasamit C. Saengsuwan P. Boonserm P. Thamjarongwong B. Singkhamanan K. Optimization of cryoprotectants for freeze-dried potential probiotic Enterococcus faecalis and evaluation of its storage stability. Drying Technology. 2022; 40(11):2283-92. doi: 10.1080/07373937.2021.1931294
43. Egorov N.S. Osnovy ucheniya ob antibiotikakh [Fundamentals of the doctrine of antibiotics]. Izd-vo MGU; Nauka, Moscow. 1994; 512 p.
44. Gavrilova NN. Ratnikova IA. Bayakyshova K. Ybysheva SD. Turlybaeva ZZh. Increase of antagonistic activity of probiotic microorganisms by additives in the composition of the nutrient medium. In Collection of scientific papers on the materials of the scientific-practical conference "Actual problems of the development of science and education", Moscow, Russia, May 5, 2014, Part 1. AR-Konsalt, Lyubertsy. 2014; 34-41.
45. Jawan R. Abbasiliasi S. Tan JS. Kapri MR. Mustafa S. Halim M. Ariff AB. Influence of type and concentration of lyoprotectants, storage temperature and storage duration on cell viability and antibacterial activity of freeze-dried lactic acid bacterium, Lactococcus lactis Gh1. Drying Technology. 2021; 40(90):1774-90. doi: 10.1080/07373937.2021.1874968
46. Savedboworn W. Teawsomboonkit K. Surichay S. Riansa-Ngawong W. Rittisak S. Charoen R. Phattayakorn K. Impact of protectants on the storage stability of freeze-dried probiotic Lactobacillus plantarum. Food Science and Biotechnology. 2019; 28(3):795-805. doi: 10.1007/s10068-018-0523-x